argenex SE $ARGX Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC trimmed its position in shares of argenex SE (NASDAQ:ARGX) by 18.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,178 shares of the company’s stock after selling 266 shares during the period. ProShare Advisors LLC’s holdings in argenex were worth $649,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. WPG Advisers LLC acquired a new position in argenex during the 1st quarter worth approximately $37,000. Brooklyn Investment Group lifted its position in shares of argenex by 102.7% during the 1st quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock worth $44,000 after purchasing an additional 38 shares during the last quarter. Banque Transatlantique SA acquired a new position in shares of argenex during the first quarter worth $62,000. Geneos Wealth Management Inc. increased its holdings in argenex by 550.0% in the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after buying an additional 99 shares during the last quarter. Finally, Raiffeisen Bank International AG purchased a new position in argenex in the first quarter valued at $76,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Down 1.2%

ARGX opened at $918.53 on Wednesday. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.13. The business’s 50 day moving average is $805.61 and its two-hundred day moving average is $676.75. The firm has a market cap of $56.55 billion, a price-to-earnings ratio of 39.44, a price-to-earnings-growth ratio of 0.95 and a beta of 0.45.

argenex (NASDAQ:ARGX) last announced its earnings results on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.07 billion. Equities analysts expect that argenex SE will post 3.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ARGX shares. Evercore ISI upped their price objective on argenex from $775.00 to $910.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Bank of America boosted their target price on argenex from $880.00 to $887.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Wedbush increased their price target on shares of argenex from $880.00 to $1,000.00 and gave the company an “outperform” rating in a research note on Friday, November 14th. Piper Sandler raised their price objective on shares of argenex from $820.00 to $930.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Finally, Citigroup upped their target price on shares of argenex from $1,041.00 to $1,124.00 and gave the company a “buy” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $903.78.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.